The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2022 | The role of cellular immunotherapies in the future treatment of HL
In this video, Yago Nieto, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into where the treatment landscape of Hodgkin lymphoma (HL) is moving, and options for patients who relapse after brentuximab vedotin and checkpoint inhibitors. Prof. Nieto highlights the potential of immunotherapies for the treatment of patients with relapsed disease, including AFM13 and autologous CD30 CAR-T therapy. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
